{
  "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed",
  "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 52,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "Clinical trial data presentation showing PFS outcomes for Arm 1 (chemo + bev) vs Arm 3 (chemo + bev + durvalumab + olaparib).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/32",
  "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed",
  "deckJsonHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed.json",
  "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.46,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "chart",
      "text": "PFS: HRD-positive subgroup (n=431, 38% population*)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "934ead5d-cb8e-45fc-8006-81eed41eb31d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.46,
        "x": 0.51,
        "y": 0.25
      },
      "kind": "chart",
      "text": "PFS: ITT (n=1130)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3687068-2471-4e5d-9749-6138277cc679",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.94,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Median follow-up in HRD-positive subgroup: Arm 1 28.8 months, Arm 3 25.6 months; ITT: Arm 1 25.5 months, Arm 3 23.3 months (median follow up in censored patients). *n=434 includes patients in all arms, Arm 1 n=144, Arm 2 n=150, Arm 3 n=140; †Medians and rates were estimated by KM method; ‡24-month PFS rates unstable. Median PFS in Arm 3 unstable. §HR and CI were estimated from a stratified Cox proportional hazards model. P value from a stratified log rank text. Model stratified by timing and outcome of cytoreductive surgery. 33 PFS = progression-free survival; HRD = homologous recombination deficient; ITT = intent-to-treat; no. = number; PC = paclitaxel/carboplatin; bev = bevacizumab; Lyn = Lynparza; m = months; HR = hazard ratio; CI = confidence interval; KM = Kaplan-Meier.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6acba4d8-edb8-431c-a180-650dee7a63b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Significant improvement in HRD-positive and overall population vs chemotherapy + bevacizumab",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d43f90ff-10a5-4156-b91e-fad46548f92f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "DUO-O Phase III",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d505f6fc-d4af-4761-a9b9-690575dd1c2e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "Kaplan-Meier Survival Analysis",
      "slug": null,
      "matchId": "ad5e9cdd-ca4e-4f7c-9fdd-0d07519971d1",
      "evidence": "Visual representation of survival probability over time with censored data points.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 52,
      "from": 26,
      "beatId": "a55635e0-23e3-4936-80d1-f995ad7f0061",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck concludes with a roadmap for future growth, potential new options for patients, and a summary of key messages",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}